PE65998A1 - Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz - Google Patents

Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz

Info

Publication number: PE65998A1
Authority: PE; Peru
Prior art keywords: preference; alkyl; substituted; oxybutyric; acids
Prior art date: 1996-05-15

Application number

PE1997000362A

Other languages

English (en)

Spanish (es)

Inventor

Jinshan Chen

David R Brittelli

Brian R Dixon

Zandt Michael C Van

Original Assignee

Bayer Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-15

Filing date

1997-05-12

Publication date

1998-10-20

1997-05-12 Application filed by Bayer Corp filed Critical Bayer Corp

1998-10-20 Publication of PE65998A1 publication Critical patent/PE65998A1/es

Links

239000003112 inhibitor Substances 0.000 title abstract 2
239000011159 matrix material Substances 0.000 title abstract 2
239000002253 acid Substances 0.000 title 1
150000007513 acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
-1 ETHYLPHENYL Chemical group 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000007536 Thrombosis Diseases 0.000 abstract 1
QKDLQFSLLCQTOH-UHFFFAOYSA-N Trichodonin Natural products C1C(O)C2C3(COC(=O)C)C(C=O)C(C)(C)CCC3OC(=O)C22C(=O)C(=C)C1C2 QKDLQFSLLCQTOH-UHFFFAOYSA-N 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
210000000845 cartilage Anatomy 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000004820 halides Chemical group 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)

PE1997000362A 1996-05-15 1997-05-12 Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz PE65998A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US64838496A	1996-05-15	1996-05-15

Publications (1)

Publication Number	Publication Date
PE65998A1 true PE65998A1 (es)	1998-10-20

Family

ID=24600568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1997000362A PE65998A1 (es)	1996-05-15	1997-05-12	Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz

Country Status (18)

Country	Link
EP (1)	EP0912487A1 (id)
JP (1)	JP3417951B2 (id)
CN (1)	CN1163466C (id)
AR (1)	AR007096A1 (id)
AU (1)	AU727648B2 (id)
CA (1)	CA2253869C (id)
CO (1)	CO4990925A1 (id)
HR (1)	HRP970246B1 (id)
ID (1)	ID20291A (id)
MY (1)	MY132470A (id)
PA (1)	PA8429401A1 (id)
PE (1)	PE65998A1 (id)
SV (1)	SV1997000034A (id)
TN (1)	TNSN97085A1 (id)
TW (1)	TW467892B (id)
WO (1)	WO1997043238A1 (id)
YU (1)	YU18797A (id)
ZA (1)	ZA974032B (id)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6288063B1 (en)	1998-05-27	2001-09-11	Bayer Corporation	Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) *	2003-09-13	2003-10-15	Glaxo Group Ltd	Therapeutically useful compounds
WO2009022740A1 (ja) *	2007-08-15	2009-02-19	Kyorin Pharmaceutical Co., Ltd.	イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
WO2015150363A1 (de)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
WO2015150350A1 (de)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
CN106458938A (zh)	2014-04-03	2017-02-22	拜耳制药股份公司	手性2,5‑二取代的环戊烷甲酸衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3827324B2 (ja) *	1994-01-22	2006-09-27	ブリテッシュバイオテックファーマシューティカルズリミテッド	金属タンパク質分解酵素阻害剤
CZ287868B6 (en)	1995-12-22	2001-02-14	Warner Lambert Co	Aromatic keto-acids and their derivatives functioning as inhibitors of matrix metalloproteinases
CO5011071A1 (es)	1996-05-15	2001-02-28	Bayer Corp	Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen

1997
- 1997-05-09 TN TNTNSN97085A patent/TNSN97085A1/fr unknown
- 1997-05-09 MY MYPI97002045A patent/MY132470A/en unknown
- 1997-05-09 ZA ZA9704032A patent/ZA974032B/xx unknown
- 1997-05-09 CO CO97025164A patent/CO4990925A1/es unknown
- 1997-05-09 HR HR970246A patent/HRP970246B1/xx not_active IP Right Cessation
- 1997-05-12 TW TW086106284A patent/TW467892B/zh not_active IP Right Cessation
- 1997-05-12 CN CNB971964599A patent/CN1163466C/zh not_active Expired - Fee Related
- 1997-05-12 EP EP97926454A patent/EP0912487A1/en not_active Withdrawn
- 1997-05-12 AR ARP970101976A patent/AR007096A1/es unknown
- 1997-05-12 WO PCT/US1997/007975 patent/WO1997043238A1/en not_active Ceased
- 1997-05-12 SV SV1997000034A patent/SV1997000034A/es not_active Application Discontinuation
- 1997-05-12 YU YU18797A patent/YU18797A/sr unknown
- 1997-05-12 CA CA002253869A patent/CA2253869C/en not_active Expired - Fee Related
- 1997-05-12 AU AU31219/97A patent/AU727648B2/en not_active Ceased
- 1997-05-12 PE PE1997000362A patent/PE65998A1/es not_active Application Discontinuation
- 1997-05-12 JP JP54100297A patent/JP3417951B2/ja not_active Expired - Fee Related
- 1997-05-12 PA PA19978429401A patent/PA8429401A1/es unknown
- 1997-05-14 ID IDP971607A patent/ID20291A/id unknown

Also Published As

Publication number	Publication date
HRP970246A2 (en)	1998-04-30
JP3417951B2 (ja)	2003-06-16
AU3121997A (en)	1997-12-05
MY132470A (en)	2007-10-31
SV1997000034A (es)	1999-07-05
HRP970246B1 (en)	2002-04-30
ID20291A (id)	1998-11-19
CN1225622A (zh)	1999-08-11
TW467892B (en)	2001-12-11
CA2253869C (en)	2003-04-22
ZA974032B (en)	1998-02-19
TNSN97085A1 (fr)	2005-03-15
YU18797A (en)	1999-11-22
CO4990925A1 (es)	2000-12-26
AR007096A1 (es)	1999-10-13
JPH11509870A (ja)	1999-08-31
WO1997043238A1 (en)	1997-11-20
EP0912487A1 (en)	1999-05-06
CN1163466C (zh)	2004-08-25
CA2253869A1 (en)	1997-11-20
PA8429401A1 (es)	2000-05-24
AU727648B2 (en)	2000-12-21

Legal Events

Date	Code	Title	Description
2000-02-29	FG	Grant, registration
2005-12-16	FD	Application declared void or lapsed

Publication	Publication Date	Title
FI955438A0 (fi)	1995-11-10	N-asyylisulfamidihappoesterit (tai -tioesterit), N-asyylisulfonamidit ja N-sulfonyylikarbamiinihappoesterit (tai -tioesterit) hyperkolesteroleemisina aineina
BRPI9915679A8 (pt)	2017-07-18	Composições e métodos para aumentar a mineralização óssea
ES2015950B3 (es)	1990-09-16	Composiciones de colagenos para arreglar huesos que contienen medula autogenica.
DE69814382D1 (de)	2003-06-12	Hydrophobe stärkederivate enthaltende kosmetische zusammensetzung
FI971312A0 (fi)	1997-03-27	Uudet prostaglandiinisyntaasin estäjät
PE20000425A1 (es)	2000-07-13	Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida
PE66898A1 (es)	1998-10-22	Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
MX16572A (es)	1993-12-01	Procedimiento para la preparacion de nuevas sulfonamidas substituidas producto obtenido y composiciones farmaceuticas que lo incluyen.
PE66198A1 (es)	1998-10-23	Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos
DE69510338D1 (de)	1999-07-22	Azirdin-derivate, deren herstellung und verwendung
ATE239719T1 (de)	2003-05-15	Kondensierte 4,5,6,7-tetrahydrobenzo c)thiophene als beschleuniger der wirkung des
FR2457296A1 (fr)	1980-12-19	Nouveaux derives de vinyl-3 cephalosporines et leur preparation
FR2745571B1 (fr)	1998-06-19	Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments, et les compositions pharmaceutiques les renfermant
DE59509355D1 (de)	2001-07-26	Stabilisatorgemisch aus chromanderivaten, organischen phosphiten oder phosphoniten und aminen
DE69329199D1 (de)	2000-09-14	Schwefel-enthaltende phosphonat-verbindungen zur behandlung von abnormalem calzium- und phosphat- metabolismus
IT1275997B1 (it)	1997-10-24	Enammine come accelleranti di vulcanizzazione per gomme naturali o sintetiche
ES2125348T3 (es)	1999-03-01	Un procedimiento para preparar un percarbonato sodico cristalino y estable.
PT95990A (pt)	1991-09-13	Processo para a preparacao de novos derivados do tiofeno
FI963168A0 (fi)	1996-08-13	Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia
PT1060161E (pt)	2003-10-31	Inibidores de metaloproteinas de matriz
BR9911585A (pt)	2001-03-20	Compostos derivados a partir de uma alfa-d-xilose, método para a preparação e uso terapêutico
KR910000638A (ko)	1991-01-29	피롤카르복시산 유도체
AR023909A1 (es)	2002-09-04	Tiadiazolsulfonamidas sustituidas, procedimiento para su preparacion, medicamentos, procedimiento para la preparacion de medicamentos, y el uso de dichoscompuestos para la preparacion de medicamentos
PT1120415E (pt)	2003-12-31	Compostos de isoxazoliltiofeno substituido
AR007096A1 (es)	1999-10-13	Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas